Number II pemphigus vulgaris

Oral Diseases

Volumn 11, Issue 3, 2005, Pages 119-130

  Black, M ^a   Mignogna, M D ^b   Scully, Crispian ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Autoimmune; Immunosuppressants; Oral; Pemphigus; Skin; Vesiculobullous

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CAPTOPRIL; CHLORAMBUCIL; CHOLINERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DESMOGLEIN 1; DESMOGLEIN 3; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETRETINATE; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PREDNISOLONE; PROSTAGLANDIN E2; RIFAMPICIN; RITUXIMAB; TACROLIMUS;

ANTIBODY DETECTION; AUTOIMMUNE DISEASE; BULLOUS SKIN DISEASE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC LINKAGE; GENETIC PREDISPOSITION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; JEW; MOUTH HYGIENE; MOUTH ULCER; PATHOGENESIS; PEMPHIGUS VULGARIS; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW;

EID: 20144375850     PISSN: 1354523X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2005.01139.x     Document Type: Review

References (190)

1. Ahmed AR, Moy R (1982). Death in pemphigus. J Am Acad Dermatol 7: 221-228.
2. Ahmed AR, Graham J, Jordon RE, Provost TT (1980). Pemphigus: current concepts. Ann Intern Med 92: 396-405.
3. Ahmed AR, Yunis EJ, Khatri K et al (1990). Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci USA 87: 7658-7662.
4. Ahmed AR, Wagner R, Khatri K et al (1991). Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci USA 88: 5056-5060.
5. Ahmed AR, Mohimen A, Yunis EJ et al (1993). Linkage of pemphigus vulgaris antibody to the major histocompatibility complex in healthy relatives of patients. J Exp Med 177: 419-424.
6. Allen CM, Camisa C (2000). Paraneoplastic pemphigus: a review of the literature. Oral Dis 6: 208-214.
7. Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR (1992). Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 90: 919-926.
8. Ameglio F, D'Auria L, Cordiali-Fei P et al (1999). Anti-intercellular substance antibody log titres are correlated with serum concentrations of interleukin-6, interleukin-15 and tumor necrosis factor-alpha in patients with Pemphigus vulgaris relationships with peripheral blood neutrophil counts, disease severity and duration and patients' age. J Biol Regul Homeost Agents 13: 220-224.
9. Anhalt GJ, Diaz LA (2001). Prospects for autoimmune disease: research advances in pemphigus. JAMA 285: 652-654.
10. Anhalt GJ, Kim SC, Stanley JR et al (1990). Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 323: 1729-1735.
11. Ayatollahi M, Joubeh S, Mortazavi H, Jefferis R, Ghaderi A (2004). IgG4 as the predominant autoantibody in sera from patients with active state of pemphigus vulgaris. J Eur Acad Dermatol Venereol 18: 241-242.
12. Balda BR, Rosenzweig D (1986). Cyclosporin A in the treatment of pemphigus foliaceus and pemphigus erythematosus. Hautarzt 37: 454-457.
13. Barnett ML (1988). Pemphigus vulgaris presenting as a gingival lesion. A case report. J Periodontol 59: 611-614.
14. Barthelemy H, Frappaz A, Cambazard F et al (1988). Treatment of nine cases of pemphigus vulgaris with cyclosporine. J Am Acad Dermatol 18: 1262-1266.
15. Basset N, Guillot B, Michel B, Meynadier J, Guilhou JJ (1987). Dapsone as initial treatment in superficial pemphigus. Report of nine cases. Arch Dermatol 123: 783-785.
16. Becker BA, Gaspari AA (1993). Pemphigus vulgaris and vegetans. Dermatol Clin 11: 429-452.
17. Bewley AP, Keefe M (1996). Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy. Br J Dermatol 135: 128-129.
18. Bezold G, Sander CA, Flaig MJ, Peter RU, Messer G (2000). Lack of detection of human herpesvirus (HHV)-8 DNA in lesional skin of German pemphigus vulgaris and pemphigus foliaceus patients. J Invest Dermatol 114: 739-741.
19. Bhol K, Natarajan K, Nagarwalla N, Mohimen A, Aoki V, Ahmed AR (1995). Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci USA 92: 5239-5243.
20. Bialy-Golan A, Brenner S, Anhalt GJ (1996). Paraneoplastic pemphigus: oral involvement as the sole manifestation. Acta Derm Venereol 76: 253-254.
21. Blaszczyk M, Chorzelski T, Daszynski J, Gaczkowski A, Jablonska S, Beutner EH (1981). Plasmapheresis as a supplementary treatment in pemphigus. Arch Immunol Ther Exp (Warsz.) 29: 763-767.
22. Bredlich RO, Grundmann-Kollmann M, Behrens S, Kerscher M, Peter RU (1999). Mycophenolate mofetil monotherapy for pemphigus vulgaris. Br J Dermatol 141: 934.
23. Brenner S, Bialy-Golan A, Ruocco V (1998). Drug-induced pemphigus. Clin Dermatol 16: 393-397.
24. Brenner S, Tur E, Shapiro J et al (2001). Pemphigus vulgaris: environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire. Int J Dermatol 40: 562-569.
25. Bystryn JC (1988). Plasmapheresis therapy of pemphigus. Arch Dermatol 124: 1702-1704.
26. Bystryn JC, Steinman NM (1996). The adjuvant therapy of pemphigus. An update. Arch Dermatol 132: 203-212.
27. Camisa C, Helm TN, Liu YC et al (1992). Paraneoplastic pemphigus: a report of three cases including one long-term survivor. J Am Acad Dermatol 27: 547-553.
28. Carcassi C, Cottoni F, Floris L et al (1996). HLA haplotypes and class II molecular alleles in Sardinian and Italian patients with pemphigus vulgaris. Tissue Antigens 48: 662-667.
29. Carson PJ, Hameed A, Ahmed AR (1996). Influence of treatment on the clinical course of pemphigus vulgaris. J Am Acad Dermatol 34: 645-652.
30. Checchi L, D'Achille C, Zelent M (1988). Desquamative gingivitis and chlorhexidine. Prev Assist Dent 14: 33-40.
31. Cheng SW, Kobayashi M, Kinoshita-Kuroda K, Tanikawa A, Amagai M, Nishikawa T (2002). Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol 147: 261-265.
32. Chrysomallis F, Ioannides D, Teknetzis A, Panagiotidou D, Minas A (1994). Treatment of oral pemphigus vulgaris. Int J Dermatol 33: 803-807.
33. Chryssomallis F, Dimitriades A, Chaidemenos GC, Panagiotides D, Karakatsanis G (1995). Steroid-pulse therapy in pemphigus vulgaris long term follow-up. Int J Dermatol 34: 438-442.
34. Cohen SS, Weinstein MD, Herndier BG, Anhalt GJ, Blauvelt A (1998). No evidence of human herpesvirus 8 infection in patients with paraneoplastic pemphigus, pemphigus vulgaris, or pemphigus foliaceus. J Invest Dermatol 111: 781-783.
35. Cotterill JA, Barker DJ, Millard LG (1978). Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol 98: 243.
36. Davenport S, Chen SY, Miller AS (2001). Pemphigus vulgaris: clinicopathologic review of 33 cases in the oral cavity. Int J Periodontics Restorative Dent 21: 85-90.
37. Delfino M, Suppa F, Piccirillo A (1986). Pemphigus vulgaris and ulcerative colitis. Dermatologica 172: 230.
38. Delgado JC, Yunis DE, Bozon MV et al (1996). MHC class II alleles and haplotypes in patients with pemphigus vulgaris from India. Tissue Antigens 48: 668-672.
39. Delgado JC, Hameed A, Yunis JJ et al (1997). Pemphigus vulgaris autoantibody response is linked to HLA-DQB1*0503 in Pakistani patients. Hum Immunol 57: 110-119.
40. Ding X, Aoki V, Mascaro JM Jr, Lopez-Swiderski A, Diaz LA, Fairley JA (1997). Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol 109: 592-596.
41. Ding X, Diaz LA, Fairley JA, Giudice GJ, Liu Z (1999). The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic. J Invest Dermatol 112: 739-743.
42. Dobrev H, Popova L, Vlashev D (1996). Proteinase inhibitors and pemphigus vulgaris. An in vitro and in vivo study. Arch Dermatol Res 288: 648-655.
43. Dupuy A, Viguier M, Bedane C et al (2004). Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 140: 91-96.
44. Edelson RL (1984). Extracorporeal photopheresis. Photodermatol 1: 209-210.
45. Eller J, Kest L (1941). Pemphigus: report of seventy-seven cases. Arch Dermatol 44: 337-344.
46. Engineer L, Bhol KC, Ahmed AR (2000). Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol 43: 1049-1057.
47. Enk AH, Knop J (1997). Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 350: 494.
48. Enk AH, Knop J (1999). Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol 135: 54-56.
49. Eversole LR (1994). Immunopathology of oral mucosal ulcerative, desquamative, and bullous diseases. Selective review of the literature. Oral Surg Oral Med Oral Pathol 77: 555-571.
50. Eversole LR, Kenney EB, Sabes WR (1972). Oral lesions as the initial sign in pemphigus vulgaris. Oral Surg Oral Med Oral Pathol 33: 354-361.
51. Fabbri P, Emmi L, Vignoli L et al (1986). Chronic pemphigus vulgaris associated with ulcerative rectocolitis. Apropos of a clinical case. G Ital Dermatol Venereol 121: 355-359.
52. Feliciani C, Toto P, Amerio P et al (2000). In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol 114: 71-77.
53. Feliciani C, Toto P, Wang B, Sauder DN, Amerio P, Tulli A (2003). Urokinase plasminogen activator mRNA is induced by IL-1 alpha and TNF-alpha in in vitro acantholysis. Exp Dermatol 12: 466-471.
54. Fellner MJ, Katz JM, McCabe JB (1978). Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris. Arch Dermatol 114: 889-894.
55. Femiano F, Gombos F, Scully C (2002). Pemphigus vulgaris with oral involvement: evaluation of two different systemic corticosteroid therapeutic protocols. J Eur Acad Dermatol Venereol 16: 353-356.
56. Fullerton SH, Woodley DT, Smoller BR, Anhalt GJ (1992). Paraneoplastic pemphigus with autoantibody deposition in bronchial epithelium after autologous bone marrow transplantation. JAMA 267: 1500-1502.
57. Gange RW, Rhodes EL, Edwards CO, Powell ME (1976). Pemphigus induced by rifampicin. Br J Dermatol 95: 445-448.
58. Gaspar ZS, Walkden V, Wojnarowska F (1996). Minocycline is a useful adjuvant therapy for pemphigus. Australas J Dermatol 37: 93-95.
59. Gazit E, Slomov Y, Goldberg I, Brenner S, Loewenthal R (2004). HLA-G is associated with pemphigus vulgaris in Jewish patients. Hum Immunol 65: 39-46.
60. Gellis S, Glass F (1941). Pemphigus, a survey of one hundred and seventy patients admitted to Bellevue Hospital from 1991 to 1941. Arch Dermatol 44: 321-336.
61. Goldberg I, Kashman Y, Brenner S (1999). The induction of pemphigus by phenol drugs. Int J Dermatol 38: 888-892.
62. Goon AT, Tay YK, Tan SH (2001). Pemphigus vulgaris following varicella infection. Clin Exp Dermatol 26: 661-663.
63. Grando SA (2000). Autoimmunity to keratinocyte acetylcholine receptors in pemphigus. Dermatology 201: 290-295.
64. Harman KE, Gratian MJ, Seed PT, Bhogal BS, Challacombe SJ, Black MM (2000a). Diagnosis of pemphigus by ELISA: a critical evaluation of two ELISAs for the detection of antibodies to the major pemphigus antigens, desmoglein 1 and 3. Clin Exp Dermatol 25: 236-240.
65. Harman KE, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM (2000b). A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype. Br J Dermatol 143: 343-348.
66. Harman KE, Seed PT, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM (2001). The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol 144: 775-780.
67. Harman KE, Albert S, Black MM (2003). Guidelines for the management of pemphigus vulgaris. Br J Dermatol 149: 926-937.
68. Hayag MV, Cohen JA, Kerdel FA (2000). Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol 43: 1065-1069.
69. Herbst A, Bystryn JC (2000). Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 42: 422-427.
70. Hertl M (2000). Humoral and cellular autoimmunity in autoimmune bullous skin disorders. Int Arch Allergy Immunol 122: 91-100.
71. Hertl M, Riechers R (1999). Analysis of the T cells that are potentially involved in autoantibody production in pemphigus vulgaris. J Dermatol 26: 748-752.
72. Hertl M, Amagai M, Sundaram H, Stanley J, Ishii K, Katz SI (1998a). Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals. J Invest Dermatol 110: 62-66.
73. Hertl M, Karr RW, Amagai M, Katz SI (1998b). Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3 specific T cell responses in pemphigus vulgaris patients and normals. J Invest Dermatol 110: 388-392.
74. Herzog S, Schmidt E, Goebeler M, Brocker EB, Zillikens D (2004). Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. Acta Derm Venereol 84: 48-52.
75. Ioannides D, Chrysomallis F, Bystryn JC (2000). Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 136: 868-872.
76. Ishii K, Amagai M, Ohata Y et al (2000). Development of pemphigus vulgaris in a patient with pemphigus foliaceus: antidesmoglein antibody profile shift confirmed by enzyme-linked immunosorbent assay. J Am Acad Dermatol 42: 859-861.
77. Jang HS, Oh CK, Lim JY, Jun ES, Kim YS, Kwon KS (2000). Detection of human herpesvirus 8 DNA in pemphigus and chronic blistering skin diseases. J Korean Med Sci 15: 442-448.
78. Kalish RS (2000). Pemphigus vulgaris: the other half of the story. J Clin Invest 106: 1433-1435.
79. Kanwar AJ, Dhar S (1995). Oral pemphigus vulgaris. Pediatr Dermatol 12: 195-197.
80. Kaplan RP, Potter TS, Fox JN (1992). Drug-induced pemphigus related to angiotensin-converting enzyme inhibitors. J Am Acad Dermatol 26: 364-366.
81. Kaplan I, Kodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S (2004). Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol 40: 553-562.
82. Korman NJ, Eyre RW, Zone J, Stanley JR (1991). Drug-induced pemphigus: autoantibodies directed against the pemphigus antigen complexes are present in penicillamine and captopril-induced pemphigus. J Invest Dermatol 96: 273-276.
83. Kowalewski C, Mackiewicz W, Schmitt D, Jablonska S, Haftek M (2001). Cell-cell junctions in acantholytic diseases. Junction proteins in nonimmune and autoimmune acantholysis. Arch Dermatol Res 293: 1-11.
84. Kricheli D, David M, Frusic-Zlotkin M et al (2000). The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3 and 1 in pemphigus patients and their first-degree relatives. Br J Dermatol 143: 337-342.
85. Lamey PJ, Rees TD, Binnie WH, Wright JM, Rankin KV, Simpson NB (1992). Oral presentation of pemphigus vulgaris and its response to systemic steroid therapy. Oral Surg Oral Med Oral Pathol 74: 54-57.
86. Laskaris G, Satriano RA (1993). Drug-induced blistering oral lesions. Clin Dermatol 11: 545-550.
87. Laskaris GC, Papavasiliou SS, Bovopoulou OD, Nicolis GD (1980). Association of oral pemphigus with chronic lymphocytic leukemia. Oral Surg Oral Med Oral Pathol 50: 244-249.
88. Lever WF, Schaumburg-Lever G (1977). Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol 113: 1236-1241.
89. Lever WF, Schaumburg-Lever G (1984). Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982. Arch Dermatol 120: 44-47.
90. Lin MS, Mascaro JM Jr, Liu Z, Espana A, Diaz LA (1997). The desmosome and hemidesmosome in cutaneous autoimmunity. Clin Exp Immunol 107(Suppl. 1): 9-15.
91. Lo Muzio L, Pannone G, Staibano S et al (2002). Strict correlation between uPAR and plakoglobin expression in pemphigus vulgaris. J Cutan Pathol 29: 540-548.
92. Loewenthal R, Slomov Y, Gonzalez-Escribano MF et al (2004). Common ancestral origin of pemphigus vulgaris in Jews and Spaniards: a study using microsatellite markers. Tissue Antigens 63: 326-334.
93. Loiseau P, Lecleach L, Prost C et al (2000). HLA class II polymorphism contributes to specify desmoglein derived peptides in pemphigus vulgaris and pemphigus foliaceus. J Autoimmun 15: 67-73.
94. Lombardi ML, Mercuro O, Tecame G et al (1996). Molecular analysis of HLA DRB1 and DQB1 in Italian patients with pemphigus vulgaris. Tissue Antigens 47: 228-230.
95. Lozada-Nur F, Huang MZ, Zhou GA (1991). Open preliminary clinical trial of clobetasol propionate ointment in adhesive paste for treatment of chronic oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol 71: 283-287.
96. Lubach D, Reichart P, Wellmann W (1984). Oral manifestations during the concurrent appearance of pemphigus and ulcerative colitis. Dtsch Z Mund Kiefer Gesichtschir 8: 308-312.
97. Luftl M, Stauber A, Mainka A, Klingel R, Schuler G, Hertl M (2003). Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 149: 598-605.
98. Mahe A, Flageul B, Cisse I, Keita S, Bobin P (1996). Pemphigus in Mali: a study of 30 cases. Br J Dermatol 134: 114-119.
99. Markitziu A, Pisanty S (1983). Gingival pemphigus vulgaris. Report of a case. Oral Surg Oral Med Oral Pathol 55: 250-252.
100. Mashkilleyson N, Mashkilleyson AL (1988). Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin. Acta Derm Venereol 68: 413-421.
101. Matz H, Bialy-Golan A, Brenner S (1997). Diclofenac: a new trigger of pemphigus vulgaris? Dermatology 195: 48-49.
102. Matzner Y, Erlich HA, Brautbar C et al (1995). Identical HLA class II alleles predispose to drug-triggered and idiopathic pemphigus vulgaris. Acta Derm Venereol 75: 12-14.
103. Memar OM, Rady PL, Goldblum RM, Yen A, Tyring SK (1997). Human herpesvirus 8 DNA sequences in blistering skin from patients with pemphigus. Arch Dermatol 133: 1247-1251.
104. Meurer M, Millns JL, Rogers RS III, Jordon RE (1977). Oral pemphigus vulgaris. A report of ten cases. Arch Dermatol 113: 1520-1524.
105. Mignogna MD, Lo Muzio L, Galloro G, Satriano RA, Ruocco V, Bucci E (1997). Oral pemphigus: clinical significance of esophageal involvement: report of eight cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84: 179-184.
106. Mignogna MD, Lo Muzio L, Mignogna RE, Carbone R, Ruoppo E, Bucci E (2000). Oral pemphigus: long term behaviour and clinical response to treatment with deflazacort in sixteen cases. J Oral Pathol Med 29: 145-152.
107. Mignogna MD, Pannone G, Lo Muzio L, Staibano S, Bucci E (2001). Catenin dislocation in oral pemphigus vulgaris. J Oral Pathol Med 30: 268-274.
108. Mignogna MD, Lo Muzio L, Ruoppo E, Fedele S, Lo Russo L, Bucci E (2002). High-dose intravenous 'pulse' methylprednisone in the treatment of severe oropharyngeal pemphigus: a pilot study. J Oral Pathol Med 31: 339-344.
109. Mimouni D, Nousari CH, Cummins DL, Kouba DJ, David M, Anhalt GJ (2003). Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol 49: 1059-1062.
110. Miyagawa S, Higashimine I, Iida T, Yamashina Y, Fukumoto T, Shirai T (1997). HLA-DRB1*04 and DRB1*14 alleles are associated with susceptibility to pemphigus among Japanese. J Invest Dermatol 109: 615-618.
111. Miyagawa S, Amagai M, Iida T, Yamamoto Y, Nishikawa T, Shirai T (1999). Late development of antidesmoglein 1 antibodies in pemphigus vulgaris: correlation with disease progression. Br J Dermatol 141: 1084-1087.
112. Miyagawa S, Niizeki H, Yamashina Y, Kaneshige T (2002). Genotyping for HLA-A, B and C alleles in Japanese patients with pemphigus: prevalence of Asian alleles of the HLA-B15 family. Br J Dermatol 146: 52-58.
113. Mobini N, Sarela A, Ahmed AR (1995). Intravenous immunoglobulins in the therapy of autoimmune and systemic inflammatory disorders. Ann Allergy Asthma Immunol 74: 119-128.
114. Mobini N, Yunis EJ, Alper CA et al (1997a). Identical MHC markers in non-Jewish Iranian and Ashkenazi Jewish patients with pemphigus vulgaris: possible common central Asian ancestral origin. Hum Immunol 57: 62-67.
115. Mobini N, Padilla T Jr, Ahmed AR (1997b). Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine. J Am Acad Dermatol 36: 264-266.
116. Morita H, Morisaki S, Kitano Y (1995). Clinical trial of prostaglandin E2 on the oral lesions of pemphigus vulgaris. Br J Dermatol 132: 165-166.
117. Muller S, Stanley JR (1990). Pemphigus: pemphigus vulgaris and pemphigus foliaceus. In: Wojnarowska F, Briggaman RA, eds. Management of blistering diseases. Chapman and Hall Medical: London, pp. 43-61.
118. Nguyen VT, Ndoye A, Shultz LD, Pittelkow MR, Grando SA (2000a). Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions. J Clin Invest 106: 1467-1479.
119. Nguyen VT, Ndoye A, Grando SA (2000b). Pemphigus vulgaris antibody identifies pemphaxin. A novel keratinocyte annexin-like molecule binding acetylcholine. J Biol Chem 275: 29466-29476.
120. Nguyen VT, Arredondo J, Chernyavsky AI, Pittelkow MR, Kitajima Y, Grando SA (2004). Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists. Arch Dermatol 140: 327-334.
121. Nisengard RJ, Rogers RS III (1987). The treatment of desquamative gingival lesions. J Periodontol 58: 167-172.
122. Nishifuji K, Amagai M, Kuwana M, Iwasaki T, Nishikawa T (2000). Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production. J Invest Dermatol 114: 88-94.
123. Nishikawa T, Hashimoto T, Shimizu H, Ebihara T, Amagai M (1996). Pemphigus: from immunofluorescence to molecular biology. J Dermatol Sci 12: 1-9.
124. Ong CS, Cook N, Lee S (2000). Drug-related pemphigus and angiotensin converting enzyme inhibitors. Australas J Dermatol 41: 242-246.
125. Orlowski WA, Bressman E, Doyle JL, Chasens AI (1983). Chronic pemphigus vulgaris of the gingiva. A case report with a 6-year follow-up. J Periodontol 54: 685-689.
126. Pasricha JS, Thanzama J, Khan UK (1988). Intermittent high-dose dexamethasone-cyclophosphamide therapy for pemphigus. Br J Dermatol 119: 73-77.
127. Pasricha JS, Khaitan BK, Raman RS, Chandra M (1995). Dexamethasone- cyclophosphamide pulse therapy for pemphigus. Int J Dermatol 34: 875-882.
128. Penneys NS, Eaglstein WH, Frost P (1976). Management of pemphigus with gold compounds: a long-term follow-up report. Arch Dermatol 112: 185-187.
129. Perniciaro C, Kuechle MK, Colon-Otero G, Raymond MG, Spear KL, Pittelkow MR (1994). Paraneoplastic pemphigus: a case of prolonged survival. Mayo Clin Proc 69: 851-855.
130. Piamphongsant T (1979). Treatment of pemphigus with corticosteroids and cyclophosphamide. J Dermatol 6: 359-363.
131. Pisanti S, Sharav Y, Kaufman E, Posner LN (1974). Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. Oral Surg Oral Med Oral Pathol 38: 382-387.
132. Powell AM, Albert S, Al Fares S, Harman KE, Setterfield J, Bhogal B, Black MM (2003). An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol 149: 138-145.
133. Prendiville JS, Israel DM, Wood WS, Dimmick JE (1994). Oral pemphigus vulgaris associated with inflammatory bowel disease and herpetic gingivostomatitis in an 11-year-old girl. Pediatr Dermatol 11: 145-150.
134. Proby CM, Ota T, Suzuki H et al (2000). Development of chimeric molecules for recognition and targeting of antigen-specific B cells in pemphigus vulgaris. Br J Dermatol 142: 321-330.
135. Pulkkinen L, Choi YW, Simpson A et al (2002). Loss of cell adhesion in Dsg3bal-Pas mice with homozygous deletion mutation (2079del14) in the desmoglein 3 gene. J Invest Dermatol 119: 1237-1243.
136. Puviani M, Marconi A, Cozzani E, Pincelli C (2003). Fas ligand in pemphigus sera induces keratinocyte apoptosis through the activation of caspase-8. J Invest Dermatol 120: 164-167.
137. Ramirez-Amador VA, Esquivel-Pedraza L, Orozco-Topete R (2000). Frequency of oral conditions in a dermatology clinic. Int J Dermatol 39: 501-505.
138. Robinson JC, Lozada-Nur F, Frieden I (1997). Oral pemphigus vulgaris: a review of the literature and a report on the management of 12 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84: 349-355.
139. Roenigk HH Jr, Deodhar S (1973). Pemphigus treatment with azathioprine. Clinical and immunologic correlation. Arch Dermatol 107: 353-357.
140. Rosenberg FR, Sanders S, Nelson CT (1976). Pemphigus: a 20-year review of 107 patients treated with corticosteroids. Arch Dermatol 112: 962-970.
141. Roujeau JC (1993). Drug-induced toxic epidermal necrolysis. II. Current aspects. Clin Dermatol 11: 493-500.
142. Roujeau JC, Kalis B, Lauret P et al (1982). Plasma exchange in corticosteroid-resistant pemphigus. Br J Dermatol 106: 103-104.
143. Ruocco V (1988). Plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris: a novelty or a reappraisal? Arch Dermatol 124: 1716-1718.
144. Ruocco V, Brenner S, Lombardi ML (1996a). A case of diet-related pemphigus. Dermatology 192: 373-374.
145. Ruocco V, Wolf R, Ruocco E, Baroni A (1996b). Viruses in pemphigus: a casual or causal relationship? Int J Dermatol 35: 782-784.
146. Salomon D, Saurat JH (1986). Oral gold therapy (Auranofin) in pemphigus vulgaris. Dermatologica 172: 310-314.
147. Sami N, Bhol KC, Ahmed RA (2003). Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. Eur J Dermatol 13: 377-381.
148. Sato M, Aoyama Y, Kitajima Y (2000). Assembly pathway of desmoglein 3 to desmosomes and its perturbation by pemphigus vulgaris-IgG in cultured keratinocytes, as revealed by time-lapsed labeling immunoelectron microscopy. Lab Invest 80: 1583-1592.
149. Schiltz JR, Michel B (1976). Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. J Invest Dermatol 67: 254-260.
150. Schmidt E, Klinker E, Opitz A et al (2003). Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 148: 1222-1229.
151. Schwermann M, Lechner W, Elsner C, Kirchner T (1988). Pemphigus vulgaris with involvement of duodenum and colon. Z Hautkr 63: 101-104.
152. Sciubba JJ (1996). Autoimmune aspects of pemphigus vulgaris and mucosal pemphigoid. Adv Dent Res 10: 52-56.
153. Scully C, Bagan JV (2004). Adverse drug reactions in the orofacial region. Crit Rev Oral Biol Med 15: 221-239.
154. Scully C, Challacombe SJ (2002). Pemphigus vulgaris: update on etiopathogenesis, oral manifestations, and management. Crit Rev Oral Biol Med 13: 397-408.
155. Scully C, Porter SR (1997). The clinical spectrum of desquamative gingivitis. Semin Cutan Med Surg 16: 308-313.
156. Scully C, Paes De Almeida O, Porter SR, Gilkes JJ (1999). Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. Br J Dermatol 140: 84-89.
157. Seishima M, Iwasaki-Bessho Y, Itoh Y, Nozawa Y, Amagai M, Kitajima Y (1999). Phosphatidylcholine-specific phospholipase C, but not phospholipase D, is involved in pemphigus IgG-induced signal transduction. Arch Dermatol Res 291: 606-613.
158. Shah RM, Bilimoria KF (1983). Oral pemphigus vulgaris. Clinico-pathological follow-up of 34 cases. J Oral Med 38: 170-173.
159. Shah N, Green AR, Elgart GW, Kerdel F (2000). The use of chlorambucil with prednisone in the treatment of pemphigus. J Am Acad Dermatol 42: 85-88.
160. Shapiro M, Jimenez S, Werth VP (2000). Pemphigus vulgaris induced by D-penicillamine therapy in a patient with systemic sclerosis. J Am Acad Dermatol 42: 297-299.
161. Shirakata Y, Amagai M, Hanakawa Y, Nishikawa T, Hashimoto K (1998). Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmoglein 1. J Invest Dermatol 110: 76-78.
162. Shklar G, Frim S, Flynn E (1978). Gingival lesions of pemphigus. J Periodontol 49: 428-435.
163. Sibaud V, Beylot-Barry M, Doutre MS, Beylot C (2000). Successful treatment of corticoid-resistant pemphigus with high-dose intravenous immunoglobulins. Ann Dermatol Venereol 127: 408-410.
164. Sinha AA, Brautbar C, Szafer F et al (1988). A newly characterized HLA DQ beta allele associated with pemphigus vulgaris. Science 239: 1026-1029.
165. Sirois DA, Fatahzadeh M, Roth R, Ettlin D (2000). Diagnostic patterns and delays in pemphigus vulgaris: experience with 99 patients. Arch Dermatol 136: 1569-1570.
166. Sklavounou A, Laskaris G (1983). Frequency of desquamative gingivitis in skin diseases. Oral Surg Oral Med Oral Pathol 56: 141-144.
167. Smith TJ, Bystryn JC (1999). Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol 135: 1275-1276.
168. Starzycki Z, Chorzeliski TP, Jablonska S (1998). Familial pemphigus vulgaris in mother and daughter. Int J Dermatol 37: 211-214.
169. Stone DD (1971). Rectal lesions and toxic dilatation of the colon in a case of pemphigus vulgaris. Am J Dig Dis 16: 163-166.
170. Swanson DL, Dahl MV (1981). Pemphigus vulgaris and plasma exchange: clinical and serologic studies. J Am Acad Dermatol 4: 325-328.
171. Takahashi M, Fukuda K, Sugimura T, Wakabayashi K (1998). Beta-catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors. Cancer Res 58: 42-46.
172. Torzecka JD, Narbutt J, Sysa-Jedrzejowska A et al (2003). Tumour necrosis factor-alpha polymorphism as one of the complex inherited factors in pemphigus. Mediators Inflamm 12: 303-307.
173. Toto P, Feliciani C, Amerio P et al (2000). Immune modulation in pemphigus vulgaris: role of CD28 and IL-10. J Immunol 164: 522-529.
174. Tremeau-Martinage G, Oksman F, Bazex J (1995). Immunoglobulin G subclass distribution of anti-intercellular substance antibodies in pemphigus. Ann Dermatol Venereol 122: 409-411.
175. Tsunoda K, Ota T, Suzuki H et al (2002). Pathogenic autoantibody production requires loss of tolerance against desmoglein 3 in both T and B cells in experimental pemphigus vulgaris. Eur J Immunol 32: 627-633.
176. Tufano MA, Baroni A, Buommino E, Ruocco E, Lombardi ML, Ruocco V (1999). Detection of herpesvirus DNA in peripheral blood mononuclear cells and skin lesions of patients with pemphigus by polymerase chain reaction. Br J Dermatol 141: 1033-1039.
177. Tur E, Brenner S (1998). Diet and pemphigus. In pursuit of exogenous factors in pemphigus and fogo selvagem. Arch Dermatol 134: 1406-1410.
178. Turner MS, Sutton D, Sauder DN (2000). The use of plasmapheresis anh immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol 43: 1058-1064.
179. Veldman CM, Gebhard KL, Uter W et al (2004). T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals. J Immunol 172: 3883-3892.
180. Virgili A, Trombelli L, Calura G (1992). Sudden vegetation of the mouth. Pemphigus vegetans of the mouth (Hallopeau type). Arch Dermatol 128: 398-392.
181. Wang X, Bregegere F, Frusic-Zlotkin M, Feinmesser M, Michel B, Milner Y (2004). Possible apoptotic mechanism in epidermal cell acantholysis induced by pemphigus vulgaris autoimmunoglobulins. Apoptosis 9: 131-143.
182. Weinberg MA, Abitbol TE (1995). Pemphigus vulgaris: gingival involvement. A case report. Ann Dent 54: 8-13.
183. Weinberg MA, Insler MS, Campen RB (1997). Mucocutaneous features of autoimmune blistering diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84: 517-534.
184. Werth VP (1996). Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol 132: 1435-1439.
185. Wolf R, Brenner S (1994). An active amide group in the molecule of drugs that induce pemphigus: a casual or causal relationship? Dermatology 189: 1-4.
186. Wolf R, Tamir A, Brenner S (1991). Drug-induced versus drug-triggered pemphigus. Dermatologica 182: 207-210.
187. Wong KC, Ho KK (2000). Pemphigus with pemphigoid-like presentation, associated with squamous cell carcinoma of the tongue. Australas J Dermatol 41: 178-180.
188. Wu SJ, Tanphaichitr A, Ly M (2002). Recent advances in dermatology. Clin Podiatr Med Surg 19: 65-78.
189. Wucherpfennig KW, Yu B, Bhol K et al (1995). Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci USA 92: 11935-11939.
190. Zegarelli DJ, Zegarelli EV (1977). Intraoral pemphigus vulgaris. Oral Surg Oral Med Oral Pathol 44: 384-393.